Characterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry powder inhalers

AAPS Journal

Volumn 13, Issue 1, 2011, Pages 30-43

  Kaialy, Waseem ^a,d   Martin, Gary P ^b   Ticehurst, Martyn D ^c   Royall, Paul ^b   Mohammad, Mohammad A ^d   Murphy, John ^c   Nokhodchi, Ali ^a  

^a MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d DAMASCUS UNIVERSITY   (Syrian Arab Republic)

Author keywords

Deposition study; Dry powder inhaler; Lactose; Particle engineering; Salbutamol sulphate

Indexed keywords

ALCOHOL; BUTANOL; LACTOSE; SALBUTAMOL SULFATE;

AEROSOL; ARTICLE; CHEMICAL COMPOSITION; CHEMICAL STRUCTURE; CRYSTALLIZATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; PARTICLE SIZE; POWDER INHALER;

AEROSOLS; ALBUTEROL; BRONCHODILATOR AGENTS; BUTANOLS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYSTALLIZATION; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; ETHANOL; EXCIPIENTS; IMAGE PROCESSING, COMPUTER-ASSISTED; LACTOSE; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; POWDERS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 79951988746     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-010-9241-x     Document Type: Article

References (65)

1. Bosquillon C, Rouxhet PG, Ahimou F, Simon D, Culot C, Préat V. Aerosolization properties, surface composition and physical state of spray-dried protein powders. J Contr Release. 2004;99:357-67. (Pubitemid 39296905)
2. Zanen P, Go LT, Lammers JWJ. The optimal particle size for β-adrenergic aerosols in mild asthmatics. In J Pharm. 1994;107:211-7. (Pubitemid 24182106)
3. Zanen P, Go LT, Lammers JW. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Br Med J. 1996;51:977.
4. Zanen P, Go LT, Lammers JWJ. The optimal particle size for parasympathicolytic aerosols in mild asthmatics. Int J Pharm. 1995;114:111-5. (Pubitemid 24377035)
5. Zeng XM, Martin GP, Marriott C, Pritchard J. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery. J Pharm Sci. 2001;90:1424-34. (Pubitemid 32867990)
6. Malcolmson RJ, Embleton JK. Dry powder formulations for pulmonary delivery. Pharm Sci Technol Today. 1998;1:394-8. (Pubitemid 28559134)
7. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005;50:1209-27. (Pubitemid 46187575)
8. Podczeck F. Particle-particle adhesion in pharmaceutical powder handling. Imperial College Proceeding; 1998.
9. Iida K, Leuenberger H, Fueg LM, Müller-Walz R, Okamoto H, Danjo K. Effect of mixing of fine carrier particles on dry powder inhalation property of salbutamol sulphate. Yakugaku Zasshi J Pharm Soc Jpn. 2000;120:113.
10. Zeng XM, Pandhal KH, Martin GP. The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols. Int J Pharm. 2000;197:41-52. (Pubitemid 30125776)
11. Telko MJ, Kujanpää J, Hickey AJ. Investigation of triboelectric charging in dry powder inhalers using electrical low pressure impactor (ELPI™). Int J Pharm. 2007;336:352-60. (Pubitemid 46670665)
12. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56:588.
13. French DL, Edwards DA, Niven RW. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J Aerosol Sci. 1996;27:769-83. (Pubitemid 26234318)
14. Srichana T, Martin GP, Marriott C. On the relationship between drug and carrier deposition from dry powder inhalers in vitro. Int J Pharm. 1998;167:13-23. (Pubitemid 28341504)
15. Kaialy W, Martin GP, Ticehurst MD, Momin MN, Nokhodchi A. The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient. Int J Pharm. 2010;392:178-88.
16. Kaialy W, Momin MN, Ticehurst MD, Murphy J, Nokhodchi A. Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler. Colloids Surf B Biointefaces. 2010;79:345-456.
17. Ganderton D, Kassem NM. Dry powder inhalers. Adv Pharm Sci. 1992;6:165-91.
18. Jones MD, Price R. The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations. Pharm Res. 2006;23:1665-74. (Pubitemid 44200528)
19. Zeng XM, Martin GP, Tee SK, Marriott C. The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro. Int J Pharm. 1998;176:99-110. (Pubitemid 28544976)
20. Zeng MX, Martin GP, Marriott C, Pritchard J. The use of lactose recrystallised from carbopol gels as a carrier for aerosolised salbutamol sulphate. Eur J Pharm Biopharm. 2001;1:55-62. (Pubitemid 32037042)
21. Larhrib H, Martin GP, Marriott C, Prime D. The use of engineered lactose crystals as a carrier for aerosolized salbutamol sulphate from dry powder inhalers. Proceedings of Drug Delivery to the Lungs X, London; 1999. p. 155-9.
22. Carr RL. Classifying flow properties of solids. Chem Eng. 1965;72:169-72.
23. Carr RL. Evaluating flow properties of solids. Chem Eng. 1965;72:163-8.
24. Adi S, Adi H, Tang P, Traini D, Chan HK, Young PM. Microparticle corrugation, adhesion and inhalation aerosol efficiency. Eur J Pharm Sci. 2008;35:12-8.
25. Tang P, Chan HK, Chiou H, Ogawa K, Jones MD, Adi H, et al. Characterisation and aerosolisation of mannitol particles produced via confined liquid impinging jets. Int J Pharm. 2009;367:51-7.
26. Chew NYK, Tang P, Chan HK, Raper JA. How much particle surface corrugation is sufficient to improve aerosol performance of powders? Pharm Res. 2005;22:148-52.
27. Chew NYK, Chan HK. Use of solid corrugated particles to enhance powder aerosol performance. PharmRes. 2001;18: 1570-7. (Pubitemid 33022413)
28. USP Pharmacopeia. The official compendia of standards, USP 26/NF 21. Aerosols, nasal, sprays, metered-dose inhalers, and dry powder inhalers [601]. United States Pharmacopeial Convention, Inc., Rockville, MD; 2003. p. 2114-23.
29. Dhumal RS, Biradar SV, Paradkar AR, York P. Particle engineering using sonocrystallization: salbutamol sulphate for pulmonary delivery. Int J Pharm. 2009;368:129-37.
30. Pritchard JN. The influence of lung deposition on clinical response. J Aerosol Med. 2001;14:19-26.
31. Rowe RC, Sheskey PJ, Weller PJ. Handbook of excipients, 6th edn. London: Pharmaceutical Press; 2003. p. 365.
32. Crisp JL, Dann SE, Edgar M, Blatchford CG. The effect of particle size on the dehydration/rehydration behaviour of lactose. Int J Pharm. 2010;391:38-47.
33. Gombas A, Szabo-Revesz P, Kata M, Regdon G, Erocombining double acute accents I. Quantitative determination of crystallinity of α-lactose monohydrate by DSC. J Therm Anal Calorim. 2002;68:503-10. (Pubitemid 34614450)
34. Larhrib H, Martin GP, Prime D, Marriott C. Characterisation and deposition studies of engineered lactose crystals with potential for use as a carrier for aerosolised salbutamol sulfate from dry powder inhalers. Eur J Pharm Sci. 2003;19:211-21. (Pubitemid 36918413)
35. Darcy P, Buckton G. The influence of heating/drying on the crystallisation of amorphous lactose after structural collapse. Int J Pharm. 1997;158:157-64. (Pubitemid 28012902)
36. Dhumal RS, Biradar SV, Paradkar AR, York P. Ultrasound assisted engineering of lactose crystals. Pharm Res. 2008;25:2835-44.
37. Listiohadi Y, Hourigan JA, Sleigh RW, Steele RJ. Thermal analysis of amorphous lactose and alpha lactose monohydrate. Dairy Sci Technol. 2009;89:43-67.
38. Stark JG, Wallace, HG. Chemistry data book, 2nd edn. London: John Murray; 1975. p. 122.
39. Khankari RK, Law D, Grant DJW. Determination of water content in pharmaceutical hydrates by differential scanning calorimetry. Int J Pharm. 1992;82:117-27.
40. Saleki-Gerhardt A, Ahlneck C, Zografi G. Assessment of disorder in crystalline solids. Int J Pharm. 1994;101:237-47. (Pubitemid 24025158)
41. Sebhatu T, Angberg M, Ahlneck C. Assessment of the degree of disorder in crystalline solids by isothermal microcalorimetry. Int J Pharm. 1994;104:135-44. (Pubitemid 24073697)
42. Saunders M, Podluii K, Shergill S, Buckton G, Royall PG. The potential of high speed DSC (hyper-DSC) for the detection and quantification of small amounts of amorphous content in predominantly crystalline samples. Int J Pharm. 2004;274:35-40.
43. Nakanishi K. Infrared absorption spectroscopy. Tokyo: Nankoudou; 1960. p. 49.
44. Kirk JH, Dann SE, Blatchford CG. Lactose: a definitive guide to polymorph determination. Int J Pharm. 2007;334:103-14. (Pubitemid 46402962)
45. Larhrib H, Zeng XM, Martin GP, Marriott C, Pritchard J. The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate. Int J Pharm. 1999;191:1-14. (Pubitemid 29502173)
46. Byron PR, Kelly EL, Kontny MJ, Lovering EG, Poochikian GK, Sethi S. Recommendations of the USP advisory panel on aerosols on the USP general chapters on aerosols (601) and uniformity of dosage units (905). Pharm Forum. 1994;20:7477-505.
47. Mitchell JP, Nagel MW. Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. J Aerosol Med. 2003;16:341-77. (Pubitemid 38120942)
48. Stahlhofen W, Gebhart J, Heyder J. Experimental determination of the regional deposition of aerosol particles in the human respiratory tract. Am Ind Hyg Assoc J. 1980;49:385-98.
49. Young PM, Sung A, Traini D, Kwok P, Chiou H, Chan H-K. Advances in pulmonary therapy. Advanced drug formulation design to optimize therapeutic outcomes. Pharm Res. 2007;24:963-70.
50. Katainen J, Paajanen M, Ahtola E, Pore V, Lahtinen J. Adhesion as an interplay between particle size and surface roughness. J Colloid Interface Sci. 2006;304:524-9. (Pubitemid 44750987)
51. Thi THH, Danède F, Descamps M, Flament MP. Comparison of physical and inhalation properties of spray-dried and micronized terbutaline sulphate. Eur J Pharm Biopharm. 2008;70:380-8.
52. Craig DQM, Royall PG, Kett VL, Hopton ML. The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems. Int J Pharm. 1999;179:179-207. (Pubitemid 29131430)
53. Murtomaa M, Mellin V, Harjunen P, Lankinen T, Laine E, Lehto VP. Effect of particle morphology on the triboelectrification in dry powder inhalers. Int J Pharm. 2004;282:107-14. (Pubitemid 39178488)
54. Traini D, Young PM, Thielmann F, Acharya M. The influence of lactose pseudopolymorphic form on salbutamol sulfate-lactose interactions in DPI formulations. Drug Dev Ind Pharm. 2008;34:992-1001.
55. Ticehurst MD, York P, Rowe RC, Dwivedi SK. Characterisation of the surface properties of α-lactose monohydrate with inverse gas chromatography, used to detect batch variation. Int J Pharm. 1996;141:93-9. (Pubitemid 26302915)
56. Ehler KF, Bernhard RA, Nickerson TA. Heats of adsorption of small molecules on various forms of lactose, sucrose, and glucose. J Agric Food Chem. 1979;27:921-7.
57. Shekunov BY, York P. Crystallization processes in pharmaceutical technology and drug delivery design. J Cryst Growth. 2000;211:122-36. (Pubitemid 30583697)
58. Sun C, Berg JC. Effect of moisture on the surface free energy and acid-base properties of mineral oxides. J Chrom A. 2002;969:59-72. (Pubitemid 35253803)
59. Bosquillon C, Lombry C, Preat V, Vanbever R. Comparison of particle sizing techniques in the case of inhalation dry powders. J Pharm Sci. 2001;90:2032-41. (Pubitemid 33144449)
60. Lucas P, Clarke MJ, Anderson K, Tobyn MJ, Staniforth JN. The role of fine particle excipients in pharmaceutical dry powder aerosols. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery VI. Buffalo Grove: Interpharm; 1998. p. 243-50.
61. Guchardi R, Frei M, John E, Kaerger JS. Influence of fine lactose and magnesium stearate on low dose dry powder inhaler formulations. Int J Pharm. 2008;348:10-7. (Pubitemid 350266232)
62. Guenette E, Barrett A, Kraus D, Brody R, Harding L, Magee G. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design. Int J Pharm. 2009;380:80-8.
63. Hickey AJ, Martonen TB. Behavior of hygroscopic pharmaceutical aerosols and the influence of hydrophobic additives. Pharm Res. 1993;10:1-7. (Pubitemid 23020830)
64. Pilcer G, Vanderbist F, Amighi K. Correlations between cascade impactor analysis and laser diffraction techniques for the determination of the particle size of aerosolised powder formulations. Int J Pharm. 2008;358:75-81.
65. Dunbar CA, Hickey AJ, Holzner P. Dispersion and characterization of pharmaceutical dry powder aerosols. Kona (The Council of Powder Technology of Japan). 1998;16:7-45.